194 related articles for article (PubMed ID: 32936352)
1. Effects of repeated increasing doses of cisplatin as models of acute kidney injury and chronic kidney disease in rats.
Al Za'abi M; Al Salam S; Al Suleimani Y; Ashique M; Manoj P; Nemmar A; Ali BH
Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):249-259. PubMed ID: 32936352
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin nephrotoxicity as a model of chronic kidney disease.
Shi M; McMillan KL; Wu J; Gillings N; Flores B; Moe OW; Hu MC
Lab Invest; 2018 Aug; 98(8):1105-1121. PubMed ID: 29858580
[TBL] [Abstract][Full Text] [Related]
3. Impact of Pulmonary Exposure to Cerium Oxide Nanoparticles on Experimental Acute Kidney Injury.
Nemmar A; Al-Salam S; Al Ansari Z; Alkharas ZA; Al Ahbabi RM; Beegam S; Yuvaraju P; Yasin J; Ali BH
Cell Physiol Biochem; 2019; 52(3):439-454. PubMed ID: 30873820
[TBL] [Abstract][Full Text] [Related]
4. The Salutary Effects of Diminazene, Lisinopril or Valsartan on Cisplatin - Induced Acute Kidney Injury in Rats: A Comparative Study.
Al Suleimani YM; Ali BH; Ali H; Manoj P; Almashaiki KS; Abdelrahman AM
Physiol Res; 2024 Apr; 73(2):227-237. PubMed ID: 38710058
[TBL] [Abstract][Full Text] [Related]
5. Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition.
Katagiri D; Hamasaki Y; Doi K; Negishi K; Sugaya T; Nangaku M; Noiri E
Kidney Int; 2016 Feb; 89(2):374-85. PubMed ID: 26535996
[TBL] [Abstract][Full Text] [Related]
6. Subcellular trafficking of tubular MDM2 implicates in acute kidney injury to chronic kidney disease transition during multiple low-dose cisplatin exposure.
Su H; Ye C; Lei CT; Tang H; Zeng JY; Yi F; Zhang C
FASEB J; 2020 Jan; 34(1):1620-1636. PubMed ID: 31914692
[TBL] [Abstract][Full Text] [Related]
7. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis.
Chen DQ; Feng YL; Chen L; Liu JR; Wang M; Vaziri ND; Zhao YY
Free Radic Biol Med; 2019 Apr; 134():484-497. PubMed ID: 30716432
[TBL] [Abstract][Full Text] [Related]
8. Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease.
Sharp CN; Doll MA; Megyesi J; Oropilla GB; Beverly LJ; Siskind LJ
Am J Physiol Renal Physiol; 2018 Jul; 315(1):F161-F172. PubMed ID: 29384415
[TBL] [Abstract][Full Text] [Related]
9. Kidney-Targeted Renalase Agonist Prevents Cisplatin-Induced Chronic Kidney Disease by Inhibiting Regulated Necrosis and Inflammation.
Guo X; Xu L; Velazquez H; Chen TM; Williams RM; Heller DA; Burtness B; Safirstein R; Desir GV
J Am Soc Nephrol; 2022 Feb; 33(2):342-356. PubMed ID: 34921111
[TBL] [Abstract][Full Text] [Related]
10. Alterations in Cisplatin Pharmacokinetics and Its Acute/Sub-chronic Kidney Injury over Multiple Cycles of Cisplatin Treatment in Rats.
Okada A; Fukushima K; Fujita M; Nakanishi M; Hamori M; Nishimura A; Shibata N; Sugioka N
Biol Pharm Bull; 2017; 40(11):1948-1955. PubMed ID: 29093343
[TBL] [Abstract][Full Text] [Related]
11. Repeated administration of low-dose cisplatin in mice induces fibrosis.
Sharp CN; Doll MA; Dupre TV; Shah PP; Subathra M; Siow D; Arteel GE; Megyesi J; Beverly LJ; Siskind LJ
Am J Physiol Renal Physiol; 2016 Mar; 310(6):F560-8. PubMed ID: 26739893
[TBL] [Abstract][Full Text] [Related]
12. Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease.
Landau SI; Guo X; Velazquez H; Torres R; Olson E; Garcia-Milian R; Moeckel GW; Desir GV; Safirstein R
Kidney Int; 2019 Apr; 95(4):797-814. PubMed ID: 30904067
[TBL] [Abstract][Full Text] [Related]
13. IRF-4 deficiency reduces inflammation and kidney fibrosis after folic acid-induced acute kidney injury.
Chen M; Wen X; Gao Y; Liu B; Zhong C; Nie J; Liang H
Int Immunopharmacol; 2021 Nov; 100():108142. PubMed ID: 34555644
[TBL] [Abstract][Full Text] [Related]
14. Galectin 3 inhibition attenuates renal injury progression in cisplatin-induced nephrotoxicity.
Li HY; Yang S; Li JC; Feng JX
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30455396
[TBL] [Abstract][Full Text] [Related]
15. Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease.
Faivre A; Katsyuba E; Verissimo T; Lindenmeyer M; Rajaram RD; Naesens M; Heckenmeyer C; Mottis A; Feraille E; Cippà P; Cohen C; Longchamp A; Allagnat F; Rutkowski JM; Legouis D; Auwerx J; de Seigneux S
Nephrol Dial Transplant; 2021 Jan; 36(1):60-68. PubMed ID: 33099633
[TBL] [Abstract][Full Text] [Related]
16. Subclinical chronic kidney disease modifies the diagnosis of experimental acute kidney injury.
Succar L; Pianta TJ; Davidson T; Pickering JW; Endre ZH
Kidney Int; 2017 Sep; 92(3):680-692. PubMed ID: 28476556
[TBL] [Abstract][Full Text] [Related]
17. Alleviation of cisplatin-induced acute kidney injury using phytochemical polyphenols is accompanied by reduced accumulation of indoxyl sulfate in rats.
Kusumoto M; Kamobayashi H; Sato D; Komori M; Yoshimura M; Hamada A; Kohda Y; Tomita K; Saito H
Clin Exp Nephrol; 2011 Dec; 15(6):820-30. PubMed ID: 21858734
[TBL] [Abstract][Full Text] [Related]
18. The abrupt pathological deterioration of cisplatin-induced acute kidney injury: Emerging of a critical time point.
Gong Q; Wang M; Jiang Y; Zha C; Yu D; Lei F; Luo Y; Feng Y; Yang S; Li J; Du L
Pharmacol Res Perspect; 2021 Dec; 9(6):e00895. PubMed ID: 34817124
[TBL] [Abstract][Full Text] [Related]
19. N-acetylcysteine ameliorates cisplatin-induced renal senescence and renal interstitial fibrosis through sirtuin1 activation and p53 deacetylation.
Li C; Xie N; Li Y; Liu C; Hou FF; Wang J
Free Radic Biol Med; 2019 Jan; 130():512-527. PubMed ID: 30447351
[TBL] [Abstract][Full Text] [Related]
20. Lactobacillus rhamnosus GKLC1 ameliorates cisplatin-induced chronic nephrotoxicity by inhibiting cell inflammation and apoptosis.
Tsai YS; Chen YP; Lin SW; Chen YL; Chen CC; Huang GJ
Biomed Pharmacother; 2022 Mar; 147():112701. PubMed ID: 35131657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
